肝肾综合征治疗进展

谢永鹏; 侯玥; 臧秀贤; 初喆

肝肾综合征治疗进展

吉林大学第一医院急诊科

详细信息

中图分类号: R575
计量
- 文章访问数: 3563
- HTML全文浏览量: 12
- PDF下载量: 1276
- 被引次数: 0
出版历程
- 出版日期: 2011-05-20

The development of treatment of hepatorenal syndrome

摘要

摘要: 肝肾综合征（HRS）是严重肝病常见并发症,病死率高。发病机制尚不十分明确,临床表现主要为功能性肾衰竭,对其正确诊断非常重要。治疗主要是针对循环动力学改变及肾灌注不足等环节,选择具有较强的全身血管收缩作用,而对肾动脉无影响的血管活性药,加上血管扩张剂,以逆转高动力循环状态,并借助血液净化系统改善肾功能;针对门静脉高压环节给予经颈静脉肝内门-体分流（TIPS）治疗;最佳治疗是肝移植。HRS应采取积极预防措施。
- 肝肾综合征
Abstract: Hepatorenal syndrome (HRS) is a common complication of serious liver disease with a very high mortality.Its pathogenesis is not very clear.The main clinical symptom is the functional renal failure, which is crucial for the correct diagnosis of this kind of disease.The treatment is mainly aimed at the changes in circulation and the insufficiency of renal blood capacity.We can choose the vasoactive drugs which have strong action on the systemic vaso-contraction but with a minimal effect on renal blood flow.In addition, in order to correct the states of hyperdynamic-circulation, it should be used in combination with the plasma expansion.And blood purification system can be used to improve the renal function.Transjugular intrahepatic portosystemic shunt (TIPS) should be used to reduce portal hypertension, and the best treatment for HRS is to implement liver transplantation.Strenuous efforts should be made to prevent the occurrence of HRS.
- hepatorenal syndrome

HTML全文

参考文献(30)

[1]Guevara M, Rodés J.Hepatorenal syndrome[J].Int J Biochem Cell Biol, 2005, 37 (1) :22-26.

[2]梁旭日.肝肾综合征的内科治疗进展状态综述[J].中国医药指南, 2010, 8 (9) :51-53.

[3]Duvoux C, Zanditenas D, Hezode C, et al.Effect of noradrenal and albumin in patients with type 1 hepatorenal syndrome, A pilot study[J].Hepatology, 2002, 36 (2) :374-380.

[4]Salerno F, Gerbes A, Ginos P, et al.Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis[J].Postgrad Med J, 2008, 84 (998) :662-670.

[5]Carl DE, Sanyal A.The management of hepatorenal syndrome[J].Minerva Gastroenterol Dietol, 2009, 55 (2) :207-226.

[6] 陈成伟.肝肾综合征诊治[C].2009年第五届国际暨全国肝衰竭与人工肝学术会议, 2009:25-28.

[7]兰海涛, 汤绍辉.肝肾综合征的内科治疗进展[J].中国误诊学杂志, 2008, 8 (19) :4549-4551.

[8]Gluud LL, Christensen K, Christensen E, et al.Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome[J].Hepatology, 2010, 51 (2) :576-584.

[9]Sanyal AJ, Boyer T, Garcia-Tsao G, et al.A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J].Gastroenterology.2008, 134 (5) :1360-1368.

[10]Dobre M, Demirjian S, Sehgal AR, et al.Terlipressin in hepatorenal syndrome:a systematic review and meta-analysis[J].Int Urol Nephrol, 2010, 20[Epub ahead of print].

[11]张智峰, 杨宁, 赵钢, 等.特立加压素治疗肝肾综合征的荟萃分析[J].中华医学杂志, 2009, 89 (28) :1970-1974.

[12]Meltzer J, Brentjens TE.Renal failure in patients with cirrhosis:hepatorenal syndrome and renal support strategies[J].Curr Opin Anaesthesiol, 2010, 23 (2) :139-144.

[13]Duvoux C, Zanditenas D, Hezode C, et al.Effect of noradr-enal and albumin in patients with type 1 hepatorenal syndrome, A pilot study[J].Hepatology, 2002, 36 (2) :374-380.

[14]李国永, 贾锐馨, 米立军.肝肾综合征的治疗现状[J].临床荟萃, 2007, 22 (13) :977-978.

[15]杨冬华.消化系疾病治疗学[M].北京:人民卫生出版社, 2005:734.

[16]Tandon P, Tsuyuki RT, Mitchell L, et al.The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites:a pilot study[J].Liver Int, 2009, 29 (2) :169-174.

[17]秦向荣, 生长抑素治疗I型肝肾综合征的疗效观察[J].药学与临床研究, 2007, 15 (6) :471-472.

[18]Esrailian E, Pantangco ER, Kyulo NL, et al.Octrcotide/Midodrine therapy significantly improves renal function and 30-day survivalin patients with typehepatorenal syndrome[J].Digest Dis And Scienc, 2007, 52 (3) :742-748.

[19]李定国, 范平.血管活性药在肝肾综合征中的作用[J].中华消化杂志, 2004, 24 (11) :703-704.

[20]Arroyo V, Torre A, Guevara M.Recent advances in hepatorenal syndrome[J].Trop Gastroenterol, 2005, 26 (1) :13-20.

[21]Mitzner SR, Stange J, Klammt S, et al.Albumin dialysis MARS:knowledge from 10 years of clinical investigation[J].ASAIO J, 2009, 55 (5) :498-502.

[22]Wong F, Raina N, Richardson R.Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment[J].Gut, 2010, 59 (3) :381-386.

[23]Betrosian AP, Agarwal B, Douzinas EE.Acute renal dysfunction in liver diseases.World J Gastroenterol, 2007, 13 (42) :5552-5559.

[24] 鞠卫强, 何晓顺, 朱晓峰, 等.肝移植围手术期肝肾综合征的综合治疗临床观察[C].中华医学会外科学分会第二届全国器官移植学术会议, 2004, 157-160.

[25]Rossle M, SiegertetterV, HuberM, et al.The first decade of the transjugular intrahepatic portosystemic shunt (TIPS) :state of the art[J].Liver, 1998, 11 (1) :73-89.

[26]Pomier-Layrargues G, Paquin SC, Hassoun Z, et al.Octreotide in hepatorenal syndrome:a randomized, double-blind, placebo-controlled, crossover study[J].Hepatology, 2003, 38 (1) :238-243.

[27]Kurmis TP.Transjugular intrahepatic portosystemic shunt:an analysis of outcomes[J].ANZ J Surg, 2009, 79 (10) :745-749.

[28]Bruha R, Skupiny C, Bal ihar K, et al.Diagnostics and therapy of hepatorenal syndrome.Recommendations of the working group on portal hypertension of the Czech Hepatology Society and theJ.E.Purkinje Czech Medical Society[J].Vnitr Lek, 2006, 52 (6) :649-650.

[29]Kiser TH, Maclaren R, Fish DN.Treatment of hepatorenal syndrome[J].Pharmacotherapy, 2009, 29 (10) :1196-1211.

[30]Ruiz R, Barri YM, Jennings LW, et al.Hepatorenal syndro-me:a proposal for kidney after liver transplantation (KALT) [J].Liver Transpl, 2007, 13 (6) :838-843.

施引文献

资源附件(0)

访问统计